Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Increased funding is needed to eliminate malaria across 22 Asia-Pacific countries and save an estimated 400,000 lives, according to research published in a new collection of studies on Wellcome Open Research.

A child drawing a mosquito on a blackboard
A Cambodian child teaches his classmates what he's learned about malaria control, part of MORU's activities to raise community awareness in malaria-endemic areas of the importance of malaria prevention and the importance of early treatment. © MORU 2019. Photographer: Nicky Almasy

Although Asia-Pacific countries have made significant progress towards their goal of eliminating malaria by 2030, collection researchers warn that stagnating donor funding puts at risk national malaria control efforts and access to lifesaving drugs and other tools, and could, under one potential scenario, result in as many as 845 million more malaria cases and 3.5 million deaths.

“This evidence-based investment case for the region comes from preliminary estimates to quantify the economic benefits of eliminating malaria, which could save hundreds of thousands of lives, avoid millions of malaria cases, and generate billions in healthcare savings, as well as savings from lost wages and productivity due to illness.” said collection advisor and study author Prof Richard Maude from the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.

“While the cost of eliminating malaria in the Asia Pacific is not insignificant, it will result in a large return on investment. For every additional dollar spent, there was predicted to be an overall economic benefit of USD $6 for the affected countries,” said lead study author Rima Shretta.

Study author Prof Lisa White of MORU adds, “We made these preliminary estimates using a first of its kind multispecies mathematical and economic modelling approach supported by estimated disease burden and from this we could develop an evidence-based investment case for the region.” 

Eliminating malaria in Asia-Pacific by 2030 is realistic, with significant human benefits – but only if adequately funded, say the study authors, who note that it is important to put pressure on donors and decision-makers to continue funding current efforts – including  fully funding the Global Fund at the upcoming replenishment conference this October.

“In the current climate of decreasing global malaria funding, countries with a lower malaria burden are becoming a lesser priority for donors, but sustained financing needs to be secured to realise this goal of P. falciparum and P. vivax elimination in the Asia-Pacific by 2030,” said study author Sheetal Silal from the University of Cape Town, South Africa.

“We hope to raise awareness of the need for increased investment to eliminate malaria and also the potential overall economic benefits of this investment,” said Prof Maude.

The articles in this collection include three research articles, an article on the new software tool and an editorial summarizing the new body of research. All are freely available online on Wellcome Open Research, https://wellcomeopenresearch.org/collections/cost_malaria_pred, and will undergo open peer review, where all reports are published alongside the articles with the authors’ responses.

The research is the result of partnership between the University of California San Francisco (UCSF) and the Mahidol Oxford Tropical Medicine Research Unit (MORU), with funding support by the Asian Development Bank, the Bill and Melinda Gates Foundation, and the Department of Foreign Affairs and Trade, Australian Government.

Media inquiries, kindly contact:  

Bangkok, Asia and Europe: John Bleho, +66.81.750.0539 (Thailand/WhatsApp)

USA: Laura J. Newman

UK:  Alanna Orpen

Similar stories

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.